Thermo Fisher Scientific

TMO

시가총액 US$2551억

Besides Wall Street's top-and-bottom-line estimates for Thermo Fisher (TMO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2026.

On CNBC's “Halftime Report Final Trades,” Stephen Weiss, chief investment officer and managing partner of Short Hills Capital Partners, picked U.S. 10 Year Treasury.

Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

.Danaher (DHR), one of the world's largest providers of medical diagnostics and laboratory equipment, recently announced plans to launch its first AI-powered autonomous laboratory, scheduled to operate at commercial scale in early 2027. While market trading barely moved the stock on the announcement date, the news marks a quiet turning point for life science automation.

TMO gears up for Q3 earnings, with revenue and EPS growth expected amid strong bioproduction demand, product innovations and clinical research strength.

Thermo Fisher (TMO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Thermo Fisher's growth gains momentum through innovation, acquisitions and broad end-market strength, but macroeconomic and currency risks remain.

Globus Medical, Intuitive Surgical and Thermo Fisher Scientific have been highlighted in this Industry Outlook article.

MILAN--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, is expanding its drug development, manufacturing, and clinical capabilities to help pharmaceutical and biotechnology companies navigate increasingly complex paths to commercialization, reduce friction, and maintain momentum. The company will showcase these new and expanded capabilities at CPHI Milan 2026, Oct. 6-8. Among the new offerings is OSD Express, a defined solution designed to increase predictability.

GenAI offers growth opportunities for GMED, ISRG and TMO, but evolving regulations and industry risks are likely to shape adoption.